

July 11, 2006

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Re: Appl. No. 10/733,501; Filed: December 11, 2003
For: TARGETING PROTEINS TO CELLS EXPRESSING
MANNOSE RECEPTORS VIA EXPRESSION IN
INSECT CELLS
Inventors: Alessandra D'Azzo, *et al*
Our Ref: SJ-01-0020A

Sir:

The following document is forwarded herewith for appropriate action by the U.S.
Patent and Trademark Office:

1. Response to Election of Species Requirement (3 pages).

No fee is believed to be required for consideration of this submission. If applicants
are incorrect and a fee is required the Commissioner is hereby authorized to charge such fee
to Deposit Account No. 501968.

Regards,



J. Scott Elmer
Reg. No. 36,129
Director, Office of Technology Licensing

Enclosures

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	:	
	:	
D'Azzo <i>et al.</i>	:	Art Unit: 1652
	:	
Serial No. 10/733,501	:	Examiner: Christian L. Fronda
	:	
Filed: December 11, 2003	:	Atty Docket: SJ-01-0020A
	:	
For: Targeting Proteins to Cells	:	
Expressing Mannose Receptors Via	:	
Expression in Insect Cells	:	

RESPONSE TO ELECTION OF SPECIES REQUIREMENT

Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The office action dated June 15, 2006 issued for the referenced application indicates that it is an "Election/Restriction", but the content fails to explicitly indicate whether a restriction requirement or election of species, or both, is intended. Since no grouping of claims are identified, Applicants have treated this as an election of species requirement. If a restriction requirement was intended, Applicants request immediate clarification from the examiner upon receipt of this submission.

In response to this election of species requirement, Applicants hereby elect, with traverse, the disease sialidosis and the corresponding enzyme α -Neuraminidase. Pending claims 1-6 encompass the elected species.

In accordance with election of species practice, Applicants understand that the elected disease and corresponding enzyme will be used as a guide to initiate examination. Once the claims are determined to be allowable with respect to this disease and enzyme, another disease/enzyme combination will be selected for examination in this same application. This will be followed by the selection of another disease/enzyme combination until the examiner is satisfied that the genus is allowable.

This election is made with traverse. The present invention arises from a basic discovery regarding the unique character of proteins produced in insect cells with respect to their selective uptake in cells expressing mannose receptors. The methods derived from this discovery are generic with respect to the production and use of enzymes to treat lysosomal storage disorders. Separate examination of each disease-enzyme combination is unwarranted and fails to acknowledge the general nature of the invention as described and claimed. Therefore applicants respectfully request that the required election of species requirement be reconsidered and that the subject matter of these claims be examined collectively as a single invention that applies to the genus of disease/enzyme combinations enumerated in the claims.

No fee is believed to be required for consideration of this submission. If applicants are incorrect and a fee is required the Commissioner is hereby authorized to charge such fee to Deposit Account No. 501968.

Respectfully submitted,



James Scott Elmer
Attorney for Applicant
Registration No. 36,129

St. Jude Children's Research Hospital
332 North Lauderdale
Memphis, TN 38105-2794
Telephone: 901-495-2756

Date: July 7, 2006